Share
5 min read
researchEvidence-based

ApoE4? New Brain Protection Breakthroughs Every Carrier Must See

After 70+ hours analyzing AAIC and AD/PD conferences, THIS is the video that changes everything.

T
· Reviewed by Dr. Kevin Tran, PharmD

Key takeaways · TL;DR

Dr. Kevin Tran analyzed 70+ hours of AD/PD 2025 conference sessions and found 8 breakthroughs that rewrote the Phoenix APOE4 protocol. Highlights: FINGER trial participants continuing to improve at year 4, mild brain atrophy predicting BETTER lifestyle response, and a specific nutrient blend buying patients 21 months of cognitive improvement in human trials.

Definition

Finnish multi-domain lifestyle intervention trial demonstrating lasting cognitive gains in at-risk adults, especially APOE4 carriers.

Definition

Formulated blend of synaptic-support nutrients (choline, uridine, DHA, B vitamins) shown to improve cognition in human Alzheimer trials.

After 70+ hours spent watching Alzheimer’s conferences recordings, I found it.

The presentation sessions that made me literally rewrite our entire Phoenix protocol.

You've seen me break down studies before. The good, the bad, the "meh."

But there are 2 amazing sessions in AD/PD 2025 that are just GOLD.

I cover the first session called “PREVENTION AND THERAPEUTIC INTERVENTIONS IN AD” in this video. (The second session cover will be released next week)

This gave me so much hope.

Like discovering people in the FINGER trial are still getting BETTER after 4 years. Not slowing down. Not maintaining. Actually improving brain function.

Or finding out that having mild brain atrophy might mean you'll respond BETTER to lifestyle changes. (Wait, what?)

Or that a specific nutrient blend (that you can make yourself!!) didn't just slow decline—it bought people back 21 months. Real months. Measured in real tests.

But here's the kicker:

These aren't theoretical models or mouse studies. This is human data, with actionable protocols, showing results that actually move the needle.

I turned all 8 breakthroughs into a deep-dive video. No fluff. No "maybes." Just what works, why it works, and what we do about it.

Trust me. This one's different. The video on the second session “PIVOTAL POINTS IN PREVENTION TRIALS AND THE NEW ERA OF PRECISION MEDICINE FOR ALZHEIMER’S DISEASE AND RELATED DISORDERS” will be released next week. Subscribe on Youtube and hit the notification bell to not miss it

—Kevin

P.S. Speaking of doing something about it... The Phoenix Experiment launches very soon. It's how we turn all this science into personalized N=1 experiments. If you're ready to stop reading studies and start running your own, stay tuned. Details coming next week.

Filed under
researchprotocolscognition

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

FAQ

Frequently asked questions.

Are FINGER trial participants still improving after 4 years?
Yes. Long-term follow-up of the FINGER trial (Finnish Geriatric Intervention Study) presented at AD/PD 2025 showed participants are still getting better at year 4, not just maintaining or slowing decline. This is striking because most Alzheimer prevention interventions at best slow decline. The fact that multi-domain lifestyle changes produce continued cognitive improvement years later suggests real neuroplasticity gains, especially meaningful for APOE4 carriers who respond particularly well to the FINGER protocol.
Why does mild brain atrophy predict better response to lifestyle changes?
Counterintuitive data from AD/PD 2025 showed that people with mild baseline brain atrophy actually respond BETTER to multi-domain lifestyle interventions. One hypothesis is that these individuals have more room for improvement and greater neuroplastic potential. Another is that mild atrophy identifies people whose pathology is still reversible. Either way, the finding challenges the idea that visible brain changes signal a hopeless situation, and suggests lifestyle protocols remain powerful even after early structural change.
What nutrient blend bought patients 21 months of cognitive improvement?
A specific multi-nutrient medical food combining choline, uridine, omega-3 DHA, B vitamins, and phospholipid precursors was shown in human trials to buy patients approximately 21 months of real cognitive improvement measured on standardized tests. This formulation, similar to Souvenaid, targets synaptic membrane formation and is designed to support phosphatidylcholine synthesis. The Phoenix team notes the blend can be approximated with individual supplements, though specific formulation matters for absorption and effect.
What are the 8 AD/PD 2025 breakthroughs APOE4 carriers need to know?
Dr. Kevin Tran identified 8 actionable findings from the AD/PD 2025 Prevention and Therapeutic Interventions session. They span the continued FINGER trial improvement, the surprising atrophy-response finding, the nutrient blend delivering 21 months of gain, precision medicine approaches for APOE4 subgroups, and additional biomarker and protocol insights. These form the basis of an updated Phoenix protocol focused on multi-domain, human-validated interventions rather than theoretical mechanisms.
Keep reading

Related protocols.